REG - Eden Research plc - Ecovelex 2025 Approval in Italy

Eden ResearchAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251117:nRSQ6772Ha&default-theme=true

RNS Number : 6772H  Eden Research plc  17 November 2025

As the information in this release pertains to EDEN RESEARCH PLC, this
announcement is deemed to constitute inside information as stipulated under
the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014
(the "UK MAR") which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The information is disclosed in accordance with the
Company's obligations under Article 17 of the UK MAR. Upon the publication of
this announcement, this inside information is now considered to be in the
public domain.

 

 

17 November 2025

 

Eden Research Plc

("Eden" or "Company")

 

Ecovelex 2025 Approval in Italy

 

Ecovelex has been granted temporary authorisation in Italy, providing farmers
with continued access to sustainable maize seed treatments to repel birds for
the 2026 growing season

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technologies, is pleased to announce that Ecovelex™ 2025 has been
granted temporary approval in Italy (in accordance with Reg. EU/1107/2009) for
use as a bird repellent seed treatment on maize for the 2026 growing season.

 

Sean Smith, CEO of Eden Research, commented:

 

"This most recent temporary approval effectively repeats the time-limited
permitted use of Ecovelex in Italy, which was first introduced in 2023 on a
temporary basis. It comes as welcome news to the many local maize farmers who
depend on seeds treated with Ecovelex as one of the only viable solutions left
to protect against bird infestation. The temporary approval in Italy enables
Eden to sell Ecovelex whilst we await full EU-wide authorisation, which is
expected in due course."

 

Ecovelex represents a new entrant into the seed treatment market and is a
replacement for conventional chemicals that are no longer approved in the EU
and UK. It was developed to safely tackle crop destruction caused by birds - a
major cause of losses in maize and other crops.

 

Ecovelex works by emitting an unpleasant taste or odour that repels birds,
leaving the seeds safely intact and the birds unaffected and free to find
alternative food sources.

 

The product, developed by Eden at its Oxfordshire facility, is based on Eden's
plant-derived active ingredients, which the Company has registered in the EU,
US, Mexico and elsewhere.  Ecovelex has also been formulated using Eden's
Sustaine(®) plastic-free microencapsulation system. It is designed to support
farmers as they strive to meet consumer and regulatory demands for more
sustainable agriculture.

 

In 2023, Eden submitted the regulatory dossier and application to Austria,
which is acting as the interzonal rapporteur member state on behalf of the EU.
Authorisation is expected in due course, with each EU member state then
required to ratify the authorisation or request additional information before
granting local authorisations.

 

 

 

 

 

For further information contact:

 

 Eden Research plc                                                       www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                              01285 359 555

Alex Abrey

 Cavendish Capital Markets Limited (Nominated advisor and joint broker)
 Giles Balleny / George Lawson (Corporate Finance)                       020 7220 0500

 Harriet Ward (Corporate Broking)

Michael Johnson (Sales)

 Oberon Capital (Joint Broker)                                           020 3179 5300
 Nick Lovering

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                      eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, EcovelexÔ was developed to safely tackle
crop destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

Follow Eden on LinkedIn (https://www.linkedin.com/company/eden-research-plc/)
, Twitter (https://twitter.com/edenresearch)  and YouTube
(https://www.youtube.com/@edenresearch580) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAGPGUPGUPAGMC



            Copyright 2019 Regulatory News Service, all rights reserved